Shenzhen-listed Chinese drug maker Shenzhen Hepalink Pharmaceutical Co., Ltd. has agreed to commit US$22 million to TPG Capital's biotech fund, TPG Biotechnology Partners IV, L.P., according to a regulatory filing. TPG Biotechnology Partners IV, L.P. had US$89.6 million of capital before the investment, and had invested in four companies as of June 30, 2014, says […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.